Search results for "severity"

showing 10 items of 1287 documents

Metacognition and emotion regulation as treatment targets in binge eating disorder: a network analysis study

2021

Abstract Background This study aims to examine the underlying associations between eating, affective and metacognitive symptoms in patients with binge eating disorder (BED) through network analysis (NA) in order to identify key variables that may be considered the target for psychotherapeutic interventions. Methods A total of 155 patients with BED completed measures of eating psychopathology, affective symptoms, emotion regulation and metacognition. A cross-sectional network was inferred by means of Gaussian Markov random field estimation using graphical LASSO and the extended Bayesian information criterion (EBIC-LASSO), and central symptoms of BED were identified by means of the strength c…

Nutrition and Dieteticslcsh:RC435-571MetacognitionInterpersonal communicationEmotion dysregulationmedicine.diseaseImpulse controlPsychotherapyBehavioral NeurosciencePsychiatry and Mental healthEating disordersBinge-eating disorderBinge eating disorderlcsh:PsychiatrymedicineNetwork analysisBinge severityPsychologyCentralityMetacognitionResearch ArticleNetwork analysisClinical psychologyPsychopathologyJournal of Eating Disorders
researchProduct

Clinicopathologic features and prognosis of young patients with hepatocellular carcinoma in a large German cohort.

2012

GOALS AND BACKGROUND Hepatocellular carcinoma in non-hepatitis B virus endemic areas is rare in patients younger than 40 years of age. The aim of this study was to characterize young patients in a large German cohort in comparison with older patients with regard to underlying liver disease, clinical management, and survival. STUDY We analyzed the clinical data and medical records of 1108 consecutive patients with confirmed hepatocellular carcinoma. Twenty-five patients (2%) were younger than 40 years of age. We compared this subgroup with patients older than 40 years of age. RESULTS Underlying chronic liver disease was less common in young patients and detectable in only 56% of patients. Fi…

OncologyAdultMalemedicine.medical_specialtyAgingCarcinoma HepatocellularChronic liver diseaseSeverity of Illness IndexCohort StudiesLiver diseaseYoung AdultLiver Function TestsInternal medicineGermanymedicineHumansYoung adultSurvival rateAgedbusiness.industryIncidenceLiver NeoplasmsGastroenterologyMiddle Agedmedicine.diseasePrognosisSurvival RateHepatocellular carcinomaCohortFemalebusinessFibrolamellar CarcinomaCohort studyJournal of clinical gastroenterology
researchProduct

FOXP2 polymorphisms in patients with schizophrenia.

2005

Abstract Background FOXP2 was described as the first gene involved in our ability to acquire spoken language. The main objective of this study was to compare the distribution of FOXP2 gene polymorphisms between patients with schizophrenia and healthy controls. Methods Two FOXP2 polymorphisms, Intron3a and SNP 923875, and the G→A transition in exon 14 were analysed in 149 patients with schizophrenia and schizoaffective disorders according to DSM-IV, as well as in 137 controls. All the patients showed a history of auditory hallucinations. Results The transition G→A at exon 14, detected in all the affected members in KE family, was not found in any of the analyzed samples from patients or cont…

OncologyAdultMalemedicine.medical_specialtyPsychosisGenotypeHallucinationsSeverity of Illness IndexExonPolymorphism (computer science)Internal medicinemedicineSNPHumansGenetic Predisposition to DiseaseAlleleBiological PsychiatryAllelesAgedDNA PrimersRetrospective StudiesGeneticsLanguage DisordersFOXP2 GenePolymorphism GeneticTransition (genetics)business.industryForkhead Transcription FactorsExonsMiddle Agedmedicine.diseaseIntronsDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthSchizophreniaSchizophreniaFemalebusinessTranscription FactorsSchizophrenia research
researchProduct

Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicente…

2006

Abstract Background Carboplatin/paclitaxel is the chemotherapy of choice for advanced ovarian cancer, both in first line and in platinum-sensitive recurrence. Although a significant proportion of patients have some neurotoxicity during treatment, the long-term outcome of chemotherapy-induced neuropathy has been scantly studied. We retrospectively assessed the prevalence of residual neuropathy in a cohort of patients in clinical remission after first-line carboplatin/paclitaxel for advanced ovarian cancer. Methods 120 patients have been included in this study (101 participating in a multicentre phase III trial evaluating the efficacy of consolidation treatment with topotecan, and 19 treated …

OncologyAdultmedicine.medical_specialtyCancer ResearchTime Factorsendocrine system diseasesPaclitaxelmedicine.medical_treatmentlcsh:RC254-282Severity of Illness IndexCarboplatinchemistry.chemical_compoundMedian follow-upInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineGeneticsHumansAgedRetrospective StudiesOvarian NeoplasmsChemotherapybusiness.industryCancerPeripheral Nervous System DiseasesRetrospective cohort studyMiddle Agedmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCarboplatinfemale genital diseases and pregnancy complicationsClinical trialchemistryOncologyTopotecanFemalebusinessOvarian cancerTopotecanmedicine.drugResearch Article
researchProduct

Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study

2021

Background: Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. Aims: To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Methods: The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Results: Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-u…

OncologyMaleSurvivalHepatocellular carcinomaCohort study Hepatocellular carcinoma Prognosis Sorafenib SurvivalSeverity of Illness IndexAntineoplastic Agent0302 clinical medicineProspective StudiesLiver NeoplasmsGastroenterologyMiddle AgedSorafenibPrognosisTreatment OutcomeItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCohort030211 gastroenterology & hepatologyFemaleLiver cancerCohort studymedicine.drugCohort studySorafenibCohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; Survivalmedicine.medical_specialtyCarcinoma HepatocellularPrognosiSettore MED/12 - GASTROENTEROLOGIAAntineoplastic AgentsRisk Assessment03 medical and health sciencesInternal medicinemedicineHumansneoplasmsPrognostic modelsNeoplasm StagingProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAGold standardmedicine.diseasedigestive system diseasesMulticenter studybusiness
researchProduct

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

2012

BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-preserved liver function (>95% Child-Pugh A) were randomized to receive either sorafenib 400mg or matching placebo orally b.i.d. on a continuous basis. Because HCC is a heterogeneous disease, baseline patient characteristics may affect individual responses to treatment. In a comprehensive series of exploratory subgroup analyses, data from the SHARP trial were analyzed to discern if baseline patient characteristics influenced the efficacy and safety o…

OncologyMaleTime FactorsMedizinKaplan-Meier EstimateSeverity of Illness Indexlaw.inventionAntineoplastic Agent0302 clinical medicineRandomized controlled triallawMedicineOverall survivalDisease control rateFatigueTime to progressionHazard ratioLiver Neoplasmshepatocellular carcinomaMiddle AgedSorafenib3. Good healthTumor BurdenAlcoholismSubset analysesLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaDisease Progression030211 gastroenterology & hepatologyFemaleHand-Foot SyndromeHumanmedicine.drugPhenylurea CompoundSorafenibDiarrheaNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularTime FactorAntineoplastic AgentsPlacebo03 medical and health sciencesHepatitis B ChronicInternal medicineHumansneoplasmsAgedNeoplasm StagingProportional Hazards ModelsPerformance statusHepatologybusiness.industryPhenylurea CompoundsHepatitis C Chronicmedicine.diseasedigestive system diseasesSurgeryClinical trialProportional Hazards ModelLiver functionbusinessJournal of hepatology
researchProduct

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer.

2019

To compare toxicity and response of docetaxel chemotherapy between metastatic hormone-sensitive prostate cancer (mHSPC) and castration-resistant metastatic prostate cancer (mCRPC) patients of the same therapeutic era for assessing of upfront docetaxel against the benchmark of docetaxel in the castrate resistant stage in the setting outside of clinical trials.A prospectively collected database of real-world prostate cancer patients receiving docetaxel was divided in mHSPC and mCRPC cases and retrospectively analyzed. Principal objectives were toxicity measured by the common criteria of adverse events terminology and response characterized by Prostate specific antigen decline and radiographic…

OncologyMalemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsUrologymedicine.medical_treatment030232 urology & nephrologyAntineoplastic AgentsDocetaxelSeverity of Illness Index03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansProspective StudiesStage (cooking)Adverse effectAgedNeoplasm StagingRetrospective StudiesChemotherapyPerformance statusbusiness.industryProstateMiddle AgedProstate-Specific Antigenmedicine.diseasePrognosisProgression-Free SurvivalClinical trialRadiographyProstate-specific antigenProstatic Neoplasms Castration-ResistantOncologyDocetaxelClinical Trials Phase III as Topic030220 oncology & carcinogenesisDisease ProgressionKallikreinsbusinessmedicine.drugUrologic oncology
researchProduct

Frailty syndrome is associated with changes in peripheral inflammatory markers in prostate cancer patients undergoing androgen deprivation therapy.

2019

To evaluate the role of peripheral inflammation (leukocyte differential count, the proinflammatory cytokines IL-beta, TNF-α, IL-6, IL-8, and the inflammatory markers fibrinogen and C-reactive protein [CRP]) in frailty syndrome in patients with prostate cancer (CaP) undergoing antiandrogen therapy (ADT).A total of 46 men between 51 and 92 years of age with CaP and receiving ADT were classified as frail, prefrail or robust according to the Fried scale. A geriatric assessment was performed, based on the Minimental State Examination for cognitive function, the Barthel index for basic activities of daily living, the Yesavage scale for geriatric depression, and the Athens insomnia scale. In addit…

OncologyMalemedicine.medical_specialtyUrologyFrailty syndrome030232 urology & nephrologyInflammationFibrinogenSeverity of Illness IndexProinflammatory cytokineAndrogen deprivation therapy03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansLymphocyte CountAthens insomnia scaleGeriatric AssessmentAgedAged 80 and overFrailtybusiness.industryProstatic NeoplasmsAndrogen AntagonistsMiddle Agedmedicine.diseaseCross-Sectional StudiesOncology030220 oncology & carcinogenesisBiomarker (medicine)medicine.symptomInflammation Mediatorsbusinessmedicine.drugUrologic oncology
researchProduct

Flower lose, a cell fitness marker, predicts COVID‐19 prognosis

2021

Abstract Risk stratification of COVID‐19 patients is essential for pandemic management. Changes in the cell fitness marker, hFwe‐Lose, can precede the host immune response to infection, potentially making such a biomarker an earlier triage tool. Here, we evaluate whether hFwe‐Lose gene expression can outperform conventional methods in predicting outcomes (e.g., death and hospitalization) in COVID‐19 patients. We performed a post‐mortem examination of infected lung tissue in deceased COVID‐19 patients to determine hFwe‐Lose’s biological role in acute lung injury. We then performed an observational study (n = 283) to evaluate whether hFwe‐Lose expression (in nasopharyngeal samples) could accu…

OncologyMedicine (General)medicine.medical_specialtyFlowersDiseaseQH426-470Lung injurySeverity of Illness Indexcell fitnessArticleR5-920COVID‐19Internal medicineSeverity of illnessGeneticsmedicineHumansPandemicsRetrospective StudiesReceiver operating characteristicSARS-CoV-2business.industryCOVID-19Retrospective cohort studyArticlesTriageMicrobiology Virology & Host Pathogen InteractionflowerROC CurvebiomarkerMolecular MedicineBiomarker (medicine)Observational studyprognosisbusinessBiomarkersEMBO Molecular Medicine
researchProduct